An overall feel about G1 Therapeutics Inc. (NASDAQ: GTHX) stock in the current moment?

As of close of business last night, G1 Therapeutics Inc.’s stock clocked out at $6.68, up 3.25% from its previous closing price of $6.47. In other words, the price has increased by $+0.21 from its previous closing price. On the day, 955380 shares were traded. GTHX stock price reached its highest trading level at $6.74 during the session, while it also had its lowest trading level at $6.31.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…



To gain a deeper understanding of GTHX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.90 and its Current Ratio is at 4.20. In the meantime, Its Debt-to-Equity ratio is 1.67 whereas as Long-Term Debt/Eq ratio is at 1.67.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on January 03, 2023, Reiterated its Buy rating but revised its target price to $31 from $32 previously.

On November 04, 2021, JP Morgan Downgraded its rating to Underweight which previously was Neutral and also lowered its target price recommendation from $20 to $19.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 05 when Malik Rajesh sold 729 shares for $5.41 per share. The transaction valued at 3,942 led to the insider holds 102,739 shares of the business.

Hanson James S. sold 729 shares of GTHX for $3,942 on Jan 05. The General Counsel now owns 41,087 shares after completing the transaction at $5.41 per share. On Jan 05, another insider, Moses Jennifer K., who serves as the CFO of the company, sold 729 shares for $5.41 each. As a result, the insider received 3,942 and left with 57,820 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 6.93 while its Price-to-Book (P/B) ratio in mrq is 6.24.

Stock Price History:

Over the past 52 weeks, GTHX has reached a high of $17.49, while it has fallen to a 52-week low of $3.84. The 50-Day Moving Average of the stock is 6.33, while the 200-Day Moving Average is calculated to be 8.31.

Shares Statistics:

It appears that GTHX traded 1.18M shares on average per day over the past three months and 967.2k shares per day over the past ten days. A total of 50.60M shares are outstanding, with a floating share count of 46.49M. Insiders hold about 0.90% of the company’s shares, while institutions hold 51.30% stake in the company. Shares short for GTHX as of Oct 13, 2022 were 7.04M with a Short Ratio of 2.57M, compared to 3.87M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 16.46% and a Short% of Float of 18.50%.

Earnings Estimates

As of right now, 8 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.63 for the current quarter, with a high estimate of -$0.44 and a low estimate of -$0.94, while EPS last year was -$1. The consensus estimate for the next quarter is -$0.81, with high estimates of -$0.56 and low estimates of -$0.93.

Analysts are recommending an EPS of between -$3.01 and -$3.95 for the fiscal current year, implying an average EPS of -$3.51. EPS for the following year is -$2.88, with 8 analysts recommending between -$2 and -$3.19.

Revenue Estimates

In the current quarter, 8 analysts expect revenue to total $23.27M. It ranges from a high estimate of $25.78M to a low estimate of $12M. As of the current estimate, G1 Therapeutics Inc.’s year-ago sales were $5.18M, an estimated increase of 349.20% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $15.19M, an increase of 162.10% less than the figure of $349.20% in the same quarter last year. There is a high estimate of $16.56M for the next quarter, whereas the lowest estimate is $13.5M.

A total of 8 analysts have provided revenue estimates for GTHX’s current fiscal year. The highest revenue estimate was $59.68M, while the lowest revenue estimate was $45M, resulting in an average revenue estimate of $56M. In the same quarter a year ago, actual revenue was $31.48M, up 77.90% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $88.45M in the next fiscal year. The high estimate is $106.22M and the low estimate is $59.72M. The average revenue growth estimate for next year is up 57.90% from the average revenue estimate for this year.